Sera Prognostics, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; comparative figures are for FY2022. This is an annual filing, not a standalone Q4 report. Sera is a women’s health diagnostics company whose commercial product is PreTRM, a blood test intended to assess spontaneous preterm-birth risk in singleton pregnancies.
Financial performance and liquidity
| Metric | FY2023 | FY2022 | Change |
|---|---|---|---|
| Revenue | $0.306 million | $0.268 million | +$0.038 million |
| Cost of revenue | $0.210 million | $0.193 million | +$0.017 million |
| Gross profit / margin | $0.096 million / 31.4% | $0.075 million / 28.0% | Margin improved |
| Operating expenses | $40.127 million | $45.920 million | Down $5.793 million |
| Operating loss | $39.821 million | $45.652 million | Improved $5.831 million |
| Net loss | $36.242 million | $44.186 million | Improved $7.944 million |
| Net loss per share, basic and diluted | $1.16 | $1.43 | Improved $0.27 |
| Operating cash used | $27.188 million | $34.610 million | Use decreased $7.422 million |
Revenue remains immaterial relative to expenses; substantially all near-term revenue is expected to come from PreTRM. The reduced net loss reflected lower operating expenses and higher other income, partly offset by increased research and development costs. Selling and marketing expense fell $6.350 million, while R&D rose $0.981 million. Other income, including interest and investment income, increased to $3.634 million from $1.527 million.
At December 31, 2023, cash and cash equivalents were $3.880 million and marketable securities were $76.040 million, totaling approximately $79.9 million. Current assets were $61.344 million versus current liabilities of $24.443 million. Deferred revenue was $20.235 million, up from $9.082 million; other receivables were $11.310 million, including $11.2 million of Elevance Health minimum payments received in January 2024. The company reported $25.283 million in total liabilities and $70.158 million in stockholders’ equity. Finance lease obligations totaled $0.636 million; no credit facility or committed source of capital was reported.
Management said existing resources are expected to fund operations for at least 12 months from the financial-statement issuance date and estimated cash runway into 2027 under its operating plan. These statements accompany continued losses and negative operating cash flow; the company says additional funding may be needed. The audited financial statements received an unqualified opinion; the auditor did not attest to internal-control effectiveness.
Material developments, outlook and risks
- Clinical evidence: In December 2023, the PRIME study’s Data Safety Monitoring Board recommended stopping enrollment after a planned interim analysis met stopping criteria for statistical significance on either co-primary endpoint. Enrollment stopped; full analyses and peer-reviewed publication were pending. The company also reported that AVERT met both co-primary endpoints, with statistically significant improvements, but detailed results were still being prepared for publication.
- Commercial strategy: Sera is focusing near-term sales on institutional customers while generating additional clinical evidence. It expects 2024 selling and marketing expense to decrease, R&D expense to decrease slightly following PRIME enrollment cessation, and G&A expense to remain level or decrease slightly. Longer-term costs may rise with pipeline development and commercialization. No quantified revenue or profitability guidance was provided.
- Elevance Health concentration: The multi-year arrangement includes minimum test purchases and payments. Elevance paid $6.0 million in 2023 relating to 2022 minimum payments; the 2023 minimum payment receivable was collected in January 2024. The filing reports no material revenue from the commercial collaboration agreement in FY2023 or FY2022; contractual minimum payments are recognized as revenue as test results are delivered. Sera also paid Elevance subsidiary Carelon Research $4.0 million for research services in FY2023.
- Funding and adoption: Sera has incurred annual losses since inception, with an accumulated deficit of $246.9 million. Commercial success depends on broader provider adoption, payer coverage and reimbursement, and the ability to raise capital if needed. Management says failure to secure contracts or significant adoption could require delays, reductions, or abandonment of programs.
- Regulation and operations: PreTRM is a laboratory-developed test. FDA proposed a rule in October 2023 to phase out its general LDT enforcement discretion; the final regulatory approach and timing were uncertain in the filing. Other significant risks include customer concentration, reimbursement and billing disputes, clinical data not replicating, laboratory or supply disruption, privacy and cybersecurity, and intellectual-property protection.
- Other notable items: Sera was temporarily ineligible to file new short-form Form S-3 registration statements until June 2024 following a late Form 8-K; the company said it filed the report on July 31, 2023. No material litigation was reported. The company disclosed no cash dividends.
Most important facts for investors to verify
- Review final, peer-reviewed PRIME and AVERT results, including endpoint effect sizes, safety findings, and the full analyses underlying company-reported trial outcomes.
- Track actual PreTRM test volumes, recognized revenue, collections, deferred-revenue conversion, and payer/provider contracts—especially the terms and performance of the Elevance relationship.
- Reconcile cash runway and quarterly cash burn against the stated operating plan; assess financing needs, potential dilution, and the effect of S-3 eligibility status.
- Monitor payer coverage, reimbursement rates, prior-authorization requirements, and any billing disputes or recoupment exposure.
- Follow the final FDA LDT framework and assess any resulting authorization, clinical-study, compliance, or cost requirements for PreTRM.